Prostate Cancer

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

It took a nightmare about a second cancer to shake me out of my complacency, and I nearly called 9 1 1.

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.

My New Year's resolutions have evolved from seeking external goals to embracing personal growth and appreciating each day.

A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, here is this week’s news.

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.

A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on the appropriate options.

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the cancer space this week.

Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or intermediate-risk prostate cancer.

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.

In patients with low-grade prostate cancer, adhering to the recommended dietary guidelines may slow the risk of prostate cancer progression.

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Patients with PSMA-positive metastatic castration-resistant prostate cancer showed benefits after receiving PSMA-targeted treatment.

An expert explained how circulating tumor cell count can identify possible clinical trial participants.

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic hormone-sensitive prostate cancer.

Expert answers to patients’ questions were offered as part of the CURE® Educated Patient® Prostate Cancer Summit.

I once thought that prostate cancer should be the center of my universe, but with everything else going on, now I’m not so sure.

An expert answers prostate cancer questions from a recent CURE Educated Patient Summit.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

Meta: ONCT-534 had a well-tolerated safety profile on a twice daily dosing schedule in relapsed/refractory metastatic castration-resistant prostate cancer.

Patients with prostate cancer may differ in time to testosterone recovery, depending on the length of treatment and age, but takes six months on average.

It’s crucial for patients with prostate cancer to know that all treatments come with side effects, which may affect their quality of life.

The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment.

With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary incontinence and erectile dysfunction, an expert said.

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET imaging, an expert explained.